Skip to content
Clinical Trials – home

Sahlgrenska University Hospital-Vaestra Goetalandsregionen

Research site

Sweden Goteborgsvagen 31, Fassberg, 431 30 Molndal, Sweden

  • 9 trials recruiting
  • Dementia Alzheimer's type · Medical device site joint infection · Heart failure with preserved ejection fraction
  • Adult patients

About Specializations

Sahlgrenska University Hospital-Vaestra Goetalandsregionen in Molndal, Sweden specialises in clinical trials of conditions such as Dementia Alzheimer's type, Medical device site joint infection, Heart failure with preserved ejection fraction, Crohn's disease, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Goteborgsvagen 31, Fassberg431 30 MolndalSweden
Recruiting now
9 trials
Conditions studied
12

More sites in MolndalSweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

16 clinical trials

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Osteoarthritis

Recruiting

Study on Treating Knee Osteoarthritis with Nasal Cartilage Implantation for Patients with Patellofemoral Osteoarthritis

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:N-Tec
  • Sponsor:Universitaetsspital Basel

Study Comparing Apixaban and Warfarin for Patients with Heart Clots After a Heart Attack

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska Institutet

Diabetic foot

Recruiting

Study on Sodium Hypochlorite and Polyhexamethylene Biguanide for Healing Diabetic Foot Ulcers in Patients with Diabetes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Hypochlorite
  • Sponsor:University Of Gothenburg

Study on Reducing Prosthetic Joint Infection in Hip Replacement Patients Using Vancomycin, Tobramycin, and Saline-Infused Bone Graft

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Region Oestergoetland

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Study on Antibiotic Treatment for Hip and Knee Joint Infections Using Linezolid, Fusidic Acid, and Rifampicin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fusidic Acid
  • Sponsor:Vaestra Goetalandsregionen

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Dementia Alzheimer's type

Not yet recruiting

Study on JNJ-64042056 for Preclinical Alzheimer's Disease in Patients

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-64042056
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.